ReGen Therapeutics Plc

WELCOME TO REGEN THERAPEUTICS PLC

The core business activities of ReGen Therapeutics Plc are:

To develop a pharmaceutical business.
To develop a nutraceutical business.

ReGen Therapeutics Plc was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

In 2007 ReGen acquired the rights to develop a new use for an existing drug, zolpidem, for the treatment of secondary brain dormancy in human subjects who have suffered significant head trauma. The Company considers the zolpidem project to be particularly exciting. The clinical effect discovered in a number of ‘open’ clinical case observations in South Africa was that zolpidem can normalise areas of brain dormancy secondary to a primary lesion in brain damage conditions. The clinical effects of this dormancy reversal have been restoration of consciousness, swallowing, co-ordination and motor function after stroke and traumatic brain injury. The Company believes that the zolpidem project represents a significant medical and commercial opportunity.

The original Colostrinin™ complex has been developed as a nutraceutical product for use in the early stages of cognitive decline in humans. In July 2006, the Company announced it had signed its first deal to commercialise Colostrinin™ with Metagenics Inc., a leading developer, manufacturer and marketer of nutraceuticals based in San Clemente, California. Metagenics began to market Colostrinin™, under the brand name CogniSure™, as a nutraceutical in North America in October 2007, having launched it under its original name in Australia in July 2007. The product is being made available to the general public through professional healthcare practitioners. ReGen is also developing Colostrinin™ as a veterinary nutraceutical for companion animals.

In parallel to the development of Colostrinin™ as a nutraceutical, ReGen has continued research on the properties of the peptides contained within the Colostrinin™ complex. The peptide programme had presented some interesting compounds for further development to a pre-clinical stage. The Company’s scientists have, so far, selected three candidates, two of which may have potential utility in Alzheimer’s disease and a further candidate with potential utility in obesity.

Here we provide, in a single area, key financial data and company information of value to an analyst, shareholder or potential investor.

Last updated January 2008.